H. Lundbeck A/S held its Annual General Meeting on 29 March 2012 at the company's registered office

At the general meeting the report by the Board of Directors was adopted and the Annual Report was approved.

The general meeting approved the remuneration for the Board of Directors for 2012.

The general meeting approved the dividend of DKK 3.49 per share of DKK 5 nominal value proposed by the Board of Directors.

Mats Pettersson, Thorleif Krarup, Jes Østergaard, Christian Dyvig and Håkan Björklund were re-elected, while Melanie G. Lee was elected to the Board of Directors. Peter Kürstein did not stand for re-election. Immediately after the general meeting, the Board of Directors elected Mats Petterson as Chairman and Christian Dyvig as Deputy Chairman of the Board of Directors.

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Mats Pettersson, Thorleif Krarup and Håkan Björklund were elected as members of the Audit Committee. Mats Pettersson, Jes Østergaard and Håkan Björklund were elected as members of the Remuneration Committee. Jes Østergaard, Christian Dyvig and Håkan Björklund were elected as members of the Scientific Committee.

The Board of Directors of H. Lundbeck A/S will hereafter comprise:

• Mats Pettersson (Chairman
• Christian Dyvig (Deputy Chairman)
• Thorleif Krarup
• Melanie G. Lee
• Jes Østergaard
• Håkan Björklund
• Mona Elisabeth Elster (employee representative)
• Jørn Møller Mayntzhusen (employee representative)
• Kim Rosenville Christensen (employee representative)

Deloitte Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditor.

The proposal of the Board of Directors to amend the Company's "Remuneration guidelines for the Board of Directors and the Executive Management of H. Lundbeck A/S" was approved. The proposal of the Board of Directors to insert an authorisation to issue warrants, the proposal of the Board of Directors to amend the e-mail address in the Articles of Association and the proposal to give the Board of Directors authorisation to let the company acquire its own shares were also adopted.

No other business was transacted at the general meeting.

The Board of Directors

Financial guidance
The content of this release will have no influence on the Lundbeck Group's financial guidance for 2012 which was provided on 8 February 2012 in connection with the release of the financial results for 2011.

Lundbeck contacts

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0 billion). For more information, please visit www.lundbeck.com.